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1

Attribute description

Biomarkers, type categorical (C) or numerical (C) and short description.
Biomarker
age
sex

Type
N
C

hyper

C

DM

C

HbA1c

N

Fglu

N

Chol

N

HDL

N

Statins

C

anticoag

C

CVD

C

BMI
w/h

N
N

skinf

N

COPD
Aller d
Dr aller
Analg
Neo
Derm

C
C
C
C
C
C

OSP

C

Psy

C

MMS

N

CMV

N

EBV

N

Values range
<60, 60-65, 66-70, 71-75, 76-80, >80
F, M
Diagnosis of Hypertension Low-grade (<160/90 mm Hg; medications are not
used, or used irregularly), High-grade (>160/90 mm Hg; medications are used
regularly)
Diagnosis of Diabetes mellitus type 2 yes, Impaired glucose tolerance, No
Glycosilated Haemoglobin (%) - a marker of an average blood glucosein a
three-month period Please, split the range of values into tertiles or quartiles,
as appropriate
Fasting glucose (mmol/L) - a marker of glucose metabolism
Total cholesterol Please, split the range of values into tertiles or quartiles, as
appropriate
HDL-cholesterol Please, split the range of values into tertiles or quartiles, as
appropriate
Statins use Yes, No
Therapy with oral anticoagulant drug (warfarin), therapy with antiaggregant
drug (aspirin), therapy with antiaggregant plant drug (ginkgo)
Cardiovascular disease. No, myocardial infarction/angina/history of
revascularization, chronic myocardiopathy with atrial fibrillation, chronic
myocardiopathy without atrial fibrillation, stroke/transient ischaemic cerebral
event, carotid artery atherosclerosis confirmed by using image techniques,
peripheral vascular disease
Body mass index (a measure of the body weight) <20, 20-25, 26-29, >=30
Weist to hip ratio - M <1.0, >=1.0; F <0.8, >=0.8
Triceps skinfold thickness Please, split the range of the values into tertiles,
separately for M and F
Chronic Obstructive Pulmonary Disease – Yes, No
Allergic disease (rhinitis/asthma) - Yes, No
Allergy to drugs - Yes, No
Long-term use of analgesics/nonsteroidal antiinflammatory drugs - Yes, No
No, malignant disease in a stable phase, skin malignancy
Chronic skin disorders Chronic dermatitis, dermatomycosis, No
Osteoporosis - an age-related disease affecting mostly women, characterized
with increased bone fragility and susceptibility for fracture.
Osteoporosis/osteopenia/no - of the radius bone; osteoporosis/osteopenia/no
- of the vertebrae; osteoporosis/osteopenia/no - of the hip
Anxyety/depression, Parkinson‘s disease, cognitive impairment, no
Neuropsychologic test for screening on cognitive impairment ”Mini Mental
Score” <10 severe cognitive imapirment, 10 - 20 moderate, 21 - 24 mild, 25 30 normal cognition
Cytomegalovirus infection (specific IgG antibodies, IU/ml). Please, split the
range of values into tertiles, or quartiles, if appropriate
Epstein-Barr virus infection (specific IgG antibodies, IU/ml). Please, split the
range of values into tertiles, or quartiles, if appropriate
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Biomarker

Type

HPA

N

LE

N

CRP

N

GAMA

N

MO

N

NEU

N

LY

N

E

N

HB

N

HTC

N

MCV

N

FE

N

ALB

N

Clear

N

HOMCIS

N

VITB12

N

FOLNA

N

INS

N

CORTIS

N

PRL

N

TSH

N

FT3

N

FT4

N

RF

N

ANA

N

IGE

N

Values range
Helicobacter pylori infection (specific IgA antibodies, IU/ml). Please, split
the range of values into tertiles, or quartiles, if appropriate
White blood cell (WBC) count (Leukocytes number × 109/L). Please, split
the range of values into tertiles, or quartiles, if appropriate
C-reactive protein (mg/L). Please, split the range of values into tertiles, or
quartiles, if appropriate
Hiper-gamma-globulinemia (g/L) - a marker of chronic inflammation
Monocytes % in WBC differential. Please, split the range of values into
tertiles, or quartiles, if appropriate
Neutrophils % in WBC differential. Please, split the range of values into
tertiles, or quartiles, if appropriate
Lymphocytes % in WBC differential Please, split the range of values into
tertiles, or quartiles, if appropriate
Red Blood Cell (RBC) count (Erythrocytes number × 101 2/L) Please, split
the range of values into tertiles, or quartiles, if appropriate
Hemoglobin (g/L). Please, split the range of values into tertiles, or quartiles,
if appropriate
Hematocrite (Erythrocyte volume blood fraction) Please, split the range of
values into tertiles, or quartiles, if appropriate
RBC Mean Cell Volume (fL). Please, split the range of values into tertiles, or
quartiles, if appropriate
Serum iron (g/L). Please, split the range of values into tertiles, or quartiles, if
appropriate
Serum albumin (g/L). Please, split the range of values into tertiles, or
quartiles, if appropriate
Creatinine clearance - an indicator of chronic renal impairment (ml/s/1.73m2 )
Please, split the range of values into tertiles, or quartiles, if appropriate
Homocystein (µmol/L)- sulphuric amino-acid Please, split the range of values
into tertiles, or quartiles, if appropriate
Vitamin B12 (pmol/L) Please, split the range of values into tertiles, or
quartiles, if appropriate
Folic acid (mM/L) Please, split the range of values into tertiles, or quartiles,
if appropriate
Serum fasting insulin (IU/ml) Please, split the range of values into tertiles, or
quartiles, if appropriate
Serum cortisol in the morning (nmol/L) Please, split the range of values into
tertiles, or quartiles, if appropriate
Prolactin in the morning (mIU/L) - the anterior pituitary gland hormone
Please, split the range of values into tertiles, or quartiles, if appropriate
Thyroid-stimulating hormone (IU/ml) - the anterior pituitary gland hormone
Please, split the range of values into tertiles, or quartiles, if appropriate
Free triiodothyronine (pmol/L) - the thyroid gland hormone Please, split the
range of values into tertiles, or quartiles, if appropriate
Free thyroxine (pmol/L)- the thyroid gland hormone Please, split the range of
values into tertiles, or quartiles, if appropriate
Rheumatoid factor - the auto-antibody, increased in patients with rheumatoid
arthritis In cases where RF is tested positive, please, split the range of values
into tertiles, or quartiles, if appropriate
Anti-nuclear antibody - the auto-antibody - a diagnostic marker in rheumatic
autoimmune diseases Please, split the range of values into tertiles, or
quartiles, if appropriate
Immunoglobuline E - a class of antibody included in the allergic reactions
Please, split the range of values into tertiles, or quartiles, if appropriate
3
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Attribute risk description

Attribute

age

sex

hyper

DM

HbA1c

FGlu

chol

HDL

Description
The strongest risk factor for death. In general: the older the person, the
higher the risk of death; although, due to the remodelling theory of aging, the
mortality rates are the highest at the age of around 75, due to the chronic
disease burden; after the age of 80, the population mortality curve starts to
slowdown, reflecting the positive selection of oldest old individuals, who are
also characterized with better coping mechanisms
For some pathophysiological aspects of ageing, such as diabetes and metabolic
syndrome, there is a presumption that men and women use different
pathways to attain ageing diseases and premature mortality (or longevity)
Hypertension is the main risk factor for cardiovascular disease - the main
mortality cause in European countries. Thus, the higher grade hypertension the stronger association with mortality. On the other hand, persons with high
grade hypertension more regularly use anti-hypertensive drugs, which may, in
turn, elicit the protective effect
Diabetes mellitus,mostly based on the pre-existing obesity, is the main risk
factor for cardiovascular disease - the main mortality cause in European
countries. Thus, diabetics might have the highest mortality risk, in
comparison to non-diabetics and those having pre-diabetes (impaired glucose
tolerance). However, there might be an alleviating effect of drug treatment, in
diabetic patients. Another contradictory argument is the fact that impaired
glucose tolerance is a condition characterized with high insulin resistance and
insulin serum concentrations -both factors confirmed as to have the strong
impact on the development of many aging diseases. In addition, among those
subjects not having diabetes, there might be some individuals characterized
with frailty - another strong mortality risk factor.
According to the above commentaries and the remodelling theory of aging,
both lowered and increased values of Hba1c - a measure of blood glucose
concentrations - may be detrimental for healthy aging and longevity. An
intriguing is also to note that, in diabetics, the HbA1c values are under the
influence of treatment
Fasting Glucose – a marker of glucose metabolism
High serum concentrations of total cholesterol is well established as the main
risk factor for cardiovascular disease and, as such, it can be also associated
with premature death. On the other hand, hypolipemic treatment with
statins is less efficient in elderly people, which may implicate weaker influence
of total cholesterol as CV risk factor, in this population group. Also, therapy
with statins, mostly used by diabetics, is known to modify the total
cholesterol levels.
High serum HDL-cholesterol concentrations (certainly ¿1.0 mmol/L) is
thought to be protective against diabetes, cardiovascular disease and
Alzheimer‘s dementia, so also against premature death. A conflicting fact is
that recent evidence implicate not only low serum concentrations of
HDL-cholesterol, but also functionally defective HDL particles, as to be
detrimental for the development of age-related chronic diseases. In general,
low serum HDL-cholesterol concentrations - a cardiovascular risk factor - can
be expected in conditions associated with insulin resistance, including obesity,
especially abdominal obesity, diabetes, hypertension, CVD, chronic renal
impairment and frailty (muscle wasting).
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Attribute

Statins

anticoag

CVD

BMI

w/h

skinf

COPD

Aller d

Dr aller

Analg

Description
Therapy with statins can modify the total cholesterol levels, so can be
protective for premature cardiovascular disease and death. Although, recent
studies indicate lower effectiveness of this therapy in elderly population. Also,
there are ambiguous results in respect to statins use and the development of
cognitive dysfunction/dementia -an emerging cause of death in modern
societies.
Oral anticoagulant/antiaggregant drug treatment is a part of a secondary
prevention strategy of CVD and can be a marker of higher CV risk and
death. On the other hand, the effect of this therapy on CVD and average life
expectancy can be beneficial. Therapy with these medications can yet be
associated with potential adverse effects and serious complications. Further,
there might be a difference between the effectiveness of anticoagulant and
antiaggregant drugs.
Cardiovascular disease is the major cause of mortality. However, there may
be differences in respect to an influence of age, gender, co-morbidity, or a
specific CVD entity (for example, stroke vs peripheral vascular disease)
Evidence say that both, low values of BMI (<20) and high values (>=30),
may contribute to CV and overall mortality. Overweight (BMI 26-29) may
also have unfavourable effect. However, there are no clear relationships
between BMI and other CV risk factors, such as lipids, hypertension and
insulin resistance, as well as in respect to gender and age differences.
Increased weist cicumference and weist to hip ratio are well established
measures of insulin resistance and CV risk factors, either being associated
with obesity, or frailty. The strength of associations with the risk of mortality
is not well known.
Increased triceps skinfold thickness is validated as an anthropometric measure
of insulin resistance state (muscle wasting). Data on the strengh of
associations towards CVD and overall mortality are not yet conclusive.
COPD is a major cause of mortality and also a CV risk factor. There may be
a survival benefit for treatment with new inhalatory drugs, however,
conclusive data are currently lacking.
Allergic diseases have in the background increased activity of the
antibody-mediated (humoral) immune response (represented with high serum
IgE concentrations). In this sense, these diseases may elicit protective effects
towards CVD and premature death, as CVD and some other aging diseases,
including dementia and cancer, use cell-mediated immunity during their
pathogenesis. Although strong evidence are lacking, recent advances in aging
process propose that the development of the main aging diseases is the result
of the unsuccessful modeling, which is associated with the bias of the immune
reaction into the cell-mediated and antibody-mediated immune response. In
this context, the bias towards humoral (antibody-mediated) immunity is
associated with the development of allergic diseases and hematoproliferative
disorders. These latter disorders, in turn, may be unfavourable for survival.
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Drug allergy might be a marker of multimorbidity and, as such, of the
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Analgesics can alleviate inflammation - according to the theory - the main
driving cause of age-related diseases. So, this therapy might be beneficial for
survival, although it can be accompanied with the serious side effects, for
example decline of renal function. Alternatively, use of these medications can
be a marker of a subgroup of patients with locomotor disease in its active
phase - characterized with increased level of inflammation, which, in turn,
may be non beneficial for survival
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Attribute

Neo

Derm

OSP

Psy

MMS

CMV

EBV

HPA

Description
Patients in the stable phase of malignant disease, including those with skin
cancer, might be in an unfavourable position in respect to survival, because of
the immune system impairment. According to the recent theories of aging,
unsuccessful remodelling of the metabolic, the immune and the
neuro-endocrine systems is responsible for increased level of inflammation and
the development of the age-related chronic diseases.
Chronic skin disorders can be a marker of the immune system dysfunction
and, as such, of an unfavourable survival pattern
Osteoporosis is an inflammation-mediated disease, so unfavourable for
survival. Overt osteoporosis may be more detrimental than the disease in its
early phase - osteopenia. Although, in an early phase of this disease, the level
of inflammation can be even at the higher level than when the disease turns
into its advanced stage. This is supported by the evidence implicating
osteopenia as a component of the frailty syndrome, characterized with
increased level of inflammation. Osteoporosis is a spot like disease, so the
larger the number of invloved sites, the greater the influence of the disease on
the survival
Anxyety-depresson and cognitive disorders are all known to activate the
hypothalamo-pituitary-adrenal (HPA) axis, which decreases an individual‘s
adaptation to infections and illnesses, mostly due to the immune system
impairment and increased secretion of inflammatory cytokines and other
mediators. So, these diseases are unfavourable for survival.
MMS < 25 is a measure of mild cognitive impairment (MCI) - an early phase
during the course of the development of dementia . Some known factors
responsible for progression of MCI to dementia include deficit of folic acid and
vitamin B12, the thyroid gland hypofunction and depression/anxyety.
Although not all persons with MCI get dementia, this condition is associated
with the immune system bias towards the cell-mediated immunity, which may
affect survival.
Latent infections reactivation is a feature of unsuccessful aging. High serum
specific IgG antibody concentrations can be used as a marker of CMV
infection reactivation. This condition is a driving force for cellular immunity
activation and exhaustion. High serum concentrations of specific IgG
antibodies have been accepted as the risk factor for frailty and premature
death.
High serum specific IgG antibody concentrations can be considered as a
marker of the immune system impairment and bias towards B lymphocytes
(humoral immunity) domination. In this sense, this condition might be
beneficial for survival, by turning the immune reaction from the cellular
towards the domination of humoral immunity, avoiding the development of
the main aging diseases, including CVD, dementia and cancer. On the other
hand, EBV infection is a driving force for the development of lymphomas and
lymphoproliferative disorders, which might be unbeneficial for survival.
Helicobacter pylori infection, a cause of chronic gastritis, is a wide-spread
condition in older population. Because of its association with increased
systemic inflammation and biased immune reaction in favour of cell-mediated
immunity, this infection might be unbeneficial for survival. Increased serum
concentrations of specific IgA antibodies (>11.1 IU/ml) is a diagnostic test
used to confirm this infection.
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Attribute

LE

CRP

GAMA

MO

NEU

LY

E

HB

HTC

Description
Leukocyte count, a marker of inflammation, is frequently included in routine
clinical checkups. According to the recent studies, increased leukocyte count,
in apparently healthy elderly population, can be used as a prognostic factor of
all-cause and cardiovascular mortality. Aspirin and nonsteroidal
antiinflammatory drugs may lower their counts.
Low grade chronic inflammation, as indicated with slightly elevated serum
concentrations of CRP (even in the upper part of the reference range), has
been considered as the main pathogenetic driving force in the progression of
the main aging chronic diseases, including CVD, dementia, osteoporosis,
cancer, autoimmune and lymphoproliferative diseases. In addition, it may
also play a major role in the development of the frailty syndrome, which in
older persons is associated with increased vulnerability for disease and death.
Phenotipically, this syndrome is characterized with lean body mass,
osteopenia, anemia and low cholesterol level.
The etiology of chronic inflammation is considered to be multifactorial. One
of the best accepted cause is obesity. In this condition, low grade
inflammation is associated with insulin resistance and impaired glucose
tolerance, increasing, in obese people, their susceptibility for diabetes and
CVD. More generally, it is thought that age-related dysfunction in the
metabolic, the neuroendocrine and the immune system, is associated with
chronic low grade inflammation.
Increased serum CRP concentrations have been found to be associated with
increased risk of CV and all-cause mortality.
Hiper-gamma-globulinemia – a marker of chronic inflammation
Mononuclear leukocytes are included in cell-mediated immunity during
pathogenesis of atherosclerotic CVD, dementia and cancer. Although
monocytes % in WBC differential is a weaker marker of cell-mediated
immunity than absolute monocytes number, it is more easily available in
clinical practice. Some age-related changes in WBC differential, including
slightly increased monocytes %, decreased lymphocytes % and increased
neutrophils %, have been found as to have predict ive power in CV and
all-risk mortality.
Some age-related changes in WBC differential, including slightly increased
monocytes %, decreased lymphocytes % and increased neutrophils %, have
been found as to have predict ive power in CV and all-risk mortality.
Some age-related changes in WBC differential, including slightly increased
monocytes %, decreased lymphocytes % and increased neutrophils %, have
been found as to have predict ive power in CV and all-risk mortality.
Erythrocytes (RBC) number is a routine laboratory test indicating blood
oxygen carrying capacity, or otherwise, used to diagnose anaemia. According
to the evidence, anemia, in older persons, as indicated by lower Hemoglobin
and Erythrocytes number, is associated with an increased mortality risk. On
the other hand, even slightly increased erythrocytes number, due to hypoxic
lung or heart diseases, can affect blood rheological properties and vascular
resistance, increasing the risk for unfavourable outcomes.
Hemoglobin is a more sensitive marker of anemia than erythrocytes number.
Both, decreased HB values (indicating anaemia) and increased HB values
(corresponding with impaired blood rheology) might be unfavourable for
survival.
Hematocrit values depend on the number and size of red blood cells. Lower
HTC may be due to anemia, or WBC hematoproliferative disorders, while
increased HTC may due to increased erythrocytes number, or enlarged RBC
MCV (macrocytic anemia). Extremes from both sides may be unfavourable
for survival.
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Attribute

MCV

FE

ALB

Clear

HOMCIS

VITB12

FOLNA

Description
The incidence of vitamin B12 and folate deficiency increases with age and
may lead to macrocytosis (indicated by increased MCV). Macrocytosis may
also develop as a result of age-related shortened RBCs life-span,
independently of vitamin B12 and folate deficiency. These large RBCs are
known to have difficulties in passing through capilary vessel network, leading
to insufficient tissue supply with oxygen and nutritients. Older people with
these disturbancies are more likely to have poorer cognitive functioning and
increased mortality. Some subpopulations of older people are especially prone
to macrocytosis, including those with chronic gastritis, chronic kidney and
heart disease, as well as those with multi-morbidity.
Testing serum iron is a part of complete blood count test. As according to the
evidence, both, lower and upper extremes of the interval values, recorded in
the sample, might be unbeneficial for survival.
Lower serum albumin, in older people, although still within the reference
range, may be a marker of low grade chronic inflammation, or more
specifically, of the frailty syndrome, characterized also with lower total
cholesterol, muscle wasing (energy-protein malnutrition)and anemia.
Decline in renal function, indicated by increased values of creatinine
clearance, is associated with a variety of pathophysiologic changes, including
hypertension, insulin resistance, other metabolic changes, increased
inflammation, the immune system dysfunction, protein malnutrition (muscle
vasting), endocrine disorders, anemia and blood rheology. Chronic renal
impairment has been recognized as the main risk factor for CVD and
dementia.
Increased serum concentrations of the amino-acid homocystein has been
found to have strong oxydative properties. Increased oxydative stress is a
driving force for the development of the main age-related chronic diseases. In
addition, hyperhomocysteinemia is an indicator of impaired DNA methylation
process and cell-cycling, which may have the greatest impact on the
functioning of cells with a high cell turn-over, such as immunocompetent
cells. Serum concentrations of homocystein > 12.5 µmol/L has been
confirmed as the risk factor for CVD and dementia. This disorder is closely
related to vitamin B12 and folic acid deficiency and frequently found in
subjects with chronic renal renal impairment, especially when it is associated
with increased level of inflammation and protein malnutrition.
Deficiency of B-vitamins, notably of vitamin B12 and folic acid, has been
confirmed as the main cause of mild hyperhomocysteinemia. The mechanism
which links these disorders into the same pathogenetic network is the
metabolic cycle of the amino acid methionine, an essential biochemical
reaction during DNA methylation reaction. This metabolic cycle is controlled
by the common set of enzymes. The activity of one of these enzymes, the
methylene tetrahydrofolate reductase. is also greatly influenced by the genetic
variations. Disorders associated with the impaired methylation reactions
include: DNA damage, genome instability, impaired cell proliferation and
insufficient neurotransmitter synthesis. These are all mechanisms during the
course of the development of the age-related diseases, including
atherosclerotic CVD, neurodegenerative disease nad cancer. The main causes
of vitamin B12 and folic acid deficiency, in older population, include low
dietary intake, impaired absorption due to chronic gastritis and oxidative
depletion due to chronic renal impairment.
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Attribute

INS

CORTIS

PRL

TSH

Description
Increased serum insulin concentrations is a clinical marker of insulin
resistance - an insufficient action of insulin on insulin-sensitive target tissues,
notably muscles. Insulin resistance is a mechanism of impaired glucose
metabolism associated with obesity, diabetes, frailty and chronic renal
impairment. Increased serum insulin concentrations, >= 85.2 pmol/L, has
been accepted as the part of the insulin resistance (Metabolic) syndrome - a
cluster of clinical features including also abdominal obesity, hypertension,
increased Triglycerides and/or decreased HDL-cholesterol serum
concentrations. The prevalence of this syndrome increases in aging
population. It is a well accepted risk factor for the development of diabetes
and CVD. Recent studies also link folate deficiency, increased level of
inflammation and impaired blood rheology, to the Metabolic syndrome. They
also emphasize the possible gender differences in the Metabolic syndrome and
its role in the development of CVD.
Serum cortisol secretion is a part of the stress-adaptive response of the
hypothalamo-pituitary-adrenal (HPA) axis. This is a dynamic feedback
network with circadian rhytmicity and pulsatile neurohormone secretion. The
HPA axis is the main neuroendocrine pathway which regulates the immune
system. Reversely, one of the most powerful stimuli of this axis is IL-6 - the
main cytokine of the inflammatory response. The complex pathogenetic
network, including obesity, dysregulation of the neuroendocrine stress axis,
increased inflammation and insulin resistance, has been found to be a risk
factor for CVD. It is not completely understood of how aging causes changes
in the HPA axis. It appears that there is no deficiency of adrenal production
of cortisol, but in its pulsatile and 24h rhytmic release. In older subjects,
serum cortisol secretion may vary more within a 24h period, as compared to
younger subjects. So, both lower and higher serum concentrations of cortisol
in the morning, might be detrimental for survival. In older population, there
is a close association between the HPA axis activation, depression / mood
disorders and neurodegenerative disorders (corresponding with cognitive
impairment and dementia). According to the recent meta-analysis, greater
diurnal decline of the HPA axis (drop between the morning and evening
cortisol), is associated with better physical performance in later life.
Epidemiologic studies have not confirmed the role of chronic activation of the
stress axis with increased mortality in later life.
The role of variations in serum prolactin concentrations, in aging diseases, has
not been clarified. Evidence indicate the association of increased serum
prolactin concentrations with the insulin resistance syndrome, chronic
inflammation, the immune system dysregulation,
depression/neurodegenerative diseases and chronic renal impairment.
Isolated finding of mildly increased serum concentrations of the hormone TSH
is a marker of subclinical form of the primary hypothyreoidism - a frequent
disorder in older population. Evidence suggest the association of this disorder
with decreased bone mineral density in postmenopausal women, increased
cholesterol and increased risk for atrial fibrillation, while evidence are
controversial on the associations with CVD, cognitive impairment and
all-cause mortality. Evidence are in favour of no harmful effect of subclinical
hypothyreoidism on the overall mortality in elderly. According to the
evidence, hypothyreoidism and moderate subclinical hypothyreoidism (TSH
> 6 IU/ml) are associated with increased CV and all-cause mortality in
patients with multiple CV risk factors and clinically manifest vascular disease.
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Attribute

FT3

FT4
RF

ANA

IGE

Description
The thyroid gland hormones are rarely changed in the elderly. The most
frequent patterns of changes include decreased fT3 and normal or increased
fT4 - a sign of nonthyroidal illness (a peripheral tissue resistance on the
action of the thyroid gland hormones due to the existence of overt chronic
diseases). This pattern of the thyroid gland hormones changes is often
associated with chronic renal impairment and is unbeneficial for survival.
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The same as noted above
Rheumatoid factor positivity can be find for years before the onset of
rheumatoid arthritis and may be considered as the marker of increased CV
risk.
Increased serum concentrations of the auto-antibody ANA can be found in
healthy elderly people, but especially in association with different chronic
diseases. It may be a marker of the bias of the immune reaction towards the
prevalence of the antibody-mediated (humoral) immunity.
The same as noted under the allergic diseases
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3

Terms extracted and the associated risk of mortality
Risk
no risk

English description
. might be beneficial for survival
. protective against premature death
. may be protective

low risk

medium low risk

medium risk

medium high risk

high risk

extremely high risk

. increasing the risk for unfavorable outcomes
. may be non beneficial for survival
. may also have unfavorable effect
. well established measures of insulin resistance and CV risk
factor
. ... The strength of associations with the risk of mortality is not
well known
. may be unfavorable for survival
. might be detrimental for survival
. unfavorable pathogenetic background
. may affect survival
. might be unbeneficial for survival
. may be detrimental for healthy aging and longevity
. might be in an unfavorable position in respect to survival
. can be expected in conditions associated with insulin
resistance, diabetes, hypertension, etc.
. may contribute to CV and overall mortality
. unfavorable for survival
. predictive power in CV and all-risk mortality
. unbeneficial for survival
. marker of increased CV risk
. strong impact on the development of many aging diseases
. may affect survival - severe cognitive impairment
. can be a marker of higher CV risk and death unfavorable
survival pattern
. has been confirmed as the risk factor for cvd and dementia
. strong mortality risk factor
. risk factor for frailty and premature death
. increased risk of CV and all-cause mortality
. increased cv and all cause mortality
. increased mortality risk
. it is a well accepted risk factor for the development of diabetes
and CVD
. main risk factor for cardiovascular disease - the main mortality
cause
. the higher grade ... the stronger association with death
. the highest mortality risk
. prognostic factor of all-cause and cardiovascular mortality
. main risk factor for cvd and dementia
. main cause of mild hyperhomocysteinemia
. major cause of mortality
. major cause of mortality and also a CV risk factor
. strongest risk factor
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Laboratory normal values

Parameter
Glucose (fglu)
HBA1c
Total cholesterol
Triglycerides
HDL-cholesterol
IgG Antibodies on cytomegalovirus
IgG antibodies Helicobacter pylori
IgA antibodies Helicobacter pylori
Total Leukocytes
(%) neutrophiles
(%) Monocytes
(%) Lymphocytes
C-reactive protein
Erythrocytes
Haemoglobin
MCV
Serum ferum
Serum albumine
Clearance
Homocisteine
γ-globuline (GAMA)
Vitamine B12
Folna (folic acid)
Serum Cortisol (in the morning)
Prolactin
TSH
fT3
fT4
Anti- nuclear Antibodies (ANA)
IgE antibodies

Reference ranges
4.4 - 6.4 mmol/L
2.8 – 3.8 %
3.5 - 5.2 mmol/L
0.5 - 1.8 mmol/L
0.9 - 1.4 mmol/L
until 0.4 IU/ml
> 11 IU/ ml
> 11 IU/ ml
3.4 - 10.0 × 109/L
44.0 - 72.0 %
2 - 12 %
20 - 46 %
do 5.0 mg/L
4.34 - 5.72 × 101 2/L
138 - 175 g/L
83.0 - 97.2 fL
11.0 - 32.0 µmol/L
35 - 52 g/L
1.6 - 2.94 ml/s/1.73m2
5,0 – 15,0 µmol/L
7.6- 1 6.5 g/L
128 – 648 pmol/L
6 - 39 mM/L
154 -638 nmol/L
M 65.7 - 439.8, F 76.3 - 400.7 mIU/L
0,46 – 4,68 Ul/ml
4.26 - 8.10 pmol/L
10 - 28.2 pmol/L
until 23 µIU/ml
<114 kIU/L
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5

Forecast arguments

This section provides an associated risk by attributes in isolation. It is important to give an importance
value to each of this rules so we know how important these are in comparison with the loops.
R1. Age

R11. w/h
- > 1 and male → medium low risk

- < 60 → low risk

- > 0.8 and f emale → medium low risk

- [60, 65] → medium low risk

R12. COPB

- [66, 70] → medium risk

- yes → extremely high risk

- [71, 75] → high risk

R13. Aller d

- [76, 80] → extremely high risk
- > 80 → medium risk

- yes → no risk

R2. Hyper

Importance [0, 100]:

- no → low risk

1. Dr allerg

- yes → high risk

- yes → medium low risk

R3. DM

R14. Analg

- yes → high risk

- yes → low risk

- IGT → medium risk

R15. Neo

R4. HbA1c

- yes → medium low risk

- < 2.8 or > 3.8 → medium low risk

R16. Derm

R5. Chol

- yes → medium low risk

- > 5.18 and < 6.19 → medium risk

R17. OSP

- >= 6.19 → high risk

- yes → medium risk

Source:
https://medlineplus.gov/
magazine/issues/summer12/articles/
summer12pg6-7.html

R18. PSY
- yes → medium risk

R6. HDL

R19. MMS

- > 1.0 → no risk

- < 10 → high risk

- < 1.0 → medium-low risk

- >= 10 and < 25 → medium low risk

R7. Statins

R20. CMV

- yes and chol > 5.18 → low risk

- > 8.1 → medium high risk

R8. Anticoag

Source: https://www.ncbi.nlm.nih.gov/
pmc/articles/PMC2877470/

- yes → medium risk

R21. HPA

R9. CVD

- > 11.1 → medium low risk

- yes → extremely high risk

R22. LE

R10. BMI

- men and > 6.8 → medium risk

- < 20 or >= 30 or [26, 29] → medium
risk

- women and > 6.5 → medium risk
13

Source:
https://www.hindawi.com/
journals/jar/2014/475093/

Source:
https://emedicine.medscape.
com/article/2085770-overview

R23. CRP
R30. ALB

- > 3 → medium high risk

- < 35 → medium high risk

Source: http://eurheartj.oxfordjournals.
org/content/31/13/1624.long

Source: Laboratory normal values

R24. MO
R31. Clear

- > 8.6 → medium risk

- men and < 2.08 → high risk

Source: Last quartile of the dataset and attribute description.

- women and < 1.58 → high risk
R32. HOMCIS

R25. Ly

- > 12.7 → medium high risk

- > 40 → medium risk
- < 20 → medium high risk

R33. VITB12

R26. E

- < 258 → medium low risk
- men and < 4.52 → medium high risk

Source: doi:10.1177/1741826711424568

- woman and < 4.10 → medium high
risk
R34. FOLNA

- men and > 5.9 → medium low risk

- < 11.4 → medium high risk

- womann and > 5.10 → medium low
risk

Source: doi:10.1177/1741826711424568

Source: http://emedicine.medscape.com/
article/2054474-overview

R35. INS

R27. Hb

- > 12.26 → medium high risk

- men and (< 140 or > 175) → medium
low risk

Source:
dc11-1657

- women and (< 123 or > 153) →
medium low risk

https://doi.org/10.2337/

R36. CORTIS

Source: http://emedicine.medscape.com/
article/2085614-overview

- < 193.3 or > 772.52 → medium low
risk

R28. HTC

Source: http://emedicine.medscape.com/
article/2088826-overview

- > 0.44 → medium low risk
- men and < 0.42 → medium low risk

R37. PRL

- women and < 0.38 → medium low
risk

- men and > 439.8 → medium risk
- women and > 400.7 → medium risk

Source: http://hyper.ahajournals.org/
content/60/3/631.long

Source:
https://doi.org/10.1093/
eurheartj/ehs233

R29. MCV
- > 96 → medium risk

R38. TSH
14

- CV D yes and > 6 → medium high
risk

Source: doi:10.1136/ard.2009.110536
R42. ANA

Source:
https://doi.org/10.1093/
eurheartj/ehs233

- > 32 → medium low risk
Source: last quartile of dataset and attribute
description.

R39. FT3
- < 4.26 → medium risk

R43. IGE

Source: doi:10.1093/ndt/gfu024

- > 114 → no risk
R40. FT4

Source: doi:10.1007/s10552-014-0489-9

- < 14 and F T 3 < 4.26 → medium risk
R44. FE
Source: doi:10.1093/ndt/gfu024
- < 10.9 or > 18 → medium low risk
Source: first and last quartile of dataset and
attribute description

R41. RF
- > 60 → medium risk
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Preferences

Preferences over pairs of attributes.
1. Age > important than sex

18. Analg > Derm

35. Skinf > ALB

2. Hyper > sex

19. Neo > Derm

36. MMSE = VITB12

3. Hyper > age

20. OSP > Neo

37. w/h > INS

4. DM > hyper

21. OSP > aller d

38. HOMCIS > Clear

5. DM > age

22. OSP > BMI

39. Clear > Derm

6. Chol = HDL

23. Psy > Derm

40. Clear > Aller d

7. FGlu = HbA1c

24. MMSE > Psy

41. Clear > BMI

8. Anticoag > statins

25. CMV = EBV

42. HOMCIS = PRL

9. CVD > BMI

26. HPA > LE

43. Clear > age

10. CVD > hypert

27. HPA = MCV

44. PRL > CORTIS

11. CVD > age

28. CRP > LE

45. PRL=TSH

12. CVD > Neo

29. MO > LE

46. TSH > Chol

13. w/h > BMI

30. LY > LE

47. TSH = FT3

14. skinf > BMI

31. HTC > HB

48. RF < CVD

15. COPB > aller d

32. E=HB

49. CRP > ANA

16. Dr aller > aller d

33. VITB12 = MCV

50. ANA = GAMA

17. Analg = CRP

34. VITB12 = FOLNA

51. IGE = Aller d

6.1

Attacks based on preferences

1. R2 ⇒ R1

12. R15 ⇒ R17

23. R29 ⇒ R28

2. R3 ⇒ R2

13. R16 ⇒ R17

24. R11 ⇒ R36

3. R3 ⇒ R1

14. R18 ⇒ R16

25. R33 ⇒ R32

4. R8 ⇒ R7

15. R18 ⇒ R13

26. R32 ⇒ R17

5. R9 ⇒ R10

16. R18 ⇒ R10

27. R32 ⇒ R13

6. R9 ⇒ R2

17. R19 ⇒ R17

28. R32 ⇒ R10

7. R9 ⇒ R1

18. R20 ⇒ R19

29. R32 ⇒ R1

8. R9 ⇒ R16

19. R22 ⇒ R23

30. R38 ⇒ R37

9. R11 ⇒ R10

20. R24 ⇒ R23

31. R39 ⇒ R5

10. R12 ⇒ R13

21. R25 ⇒ R23

32. R9 ⇒ R42

11. R14 ⇒ R13

22. R26 ⇒ R23

33. R24 ⇒ R43
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Contradictions

These are contradictions between attributes that might invalidate the use of one attribute.
1. If Age > 60 then Aller d can not exist
2. If (Age < 60 and not DM and not Hyper) or (Age between 61 and 65) then Clear is not low
3. If Clear is low then HOMCIS is not low
4. If Clear is low then PRL is not low
5. If Clear is low then TSH is not low
6. If VITB12 is not low then MCV can not be increased
7. If COPB then Aller d can not exist
8. If INS is low then w/h can not be high
9. If no CVD then no Anticoag
10. If low Chol then no Statins
11. If OSP then CRP can not be low
12. If CVD then increased Skinf
13. If BMI is high than Skinf can not be increased
14. If CVD than Skinf can not be low
15. If MMSE >= 25 then TSH can not be increased
16. If HOMCIS is low than Clear can not be low
17. If Chol is high than HTC can not be low
18. If IGE low than HPA is not high
19. If Clear is low and high CRP then low ALB.

17

20. If VITB12 is high then MCV can not be increased
21. If high HPA then low VITB12
22. If INS is low then HDL is not low
23. If DM than BMI can not be high
24. If DM than BMI can be high
Impact loops: Not implemented. 23 and 24 contradict each other.
25. If DM then w/h can not be low
26. If COPB than Skinf can not be low
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